eli lilly retatrutide study Eli Lilly's retatrutide cuts weight by 17% in diabetes trial

Today, we shared new data from the latest Phase 3 study of retatrutide, an investigational treatment being studied for adults with obesity or overweight with at least one weight-related comorbidity. Learn more:

27.90

★★★★☆4.8 (126)

watchlongevity.com | Eli Lilly's experimental obesity drug retatrutide hit its primary goal in a large Phase 3 trial, with participants losing roughly

22.50

★★★★★4.9 (98)

Eli Lilly retatrutide Phase 3 obesity trial results 2026

22.39

★★★★★5.0 (157)

Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide

28.39

★★★★★4.7 (84)

Eli Lilly's weight loss drug retatrutide clears first late-stage study

21.80

★★★★★4.9 (203)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

26.89

★★★★★5.0 (176)

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9)

27.76

★★★★★4.8 (132)